Correlation Engine 2.0
Clear Search sequence regions


  • actin (3)
  • adult (1)
  • cardiovascular disease (2)
  • cofilin (1)
  • cohort (1)
  • f actin (1)
  • humans (1)
  • improves (1)
  • mice (7)
  • mortality (1)
  • nitric oxide (1)
  • oxygen (1)
  • pathogenesis (1)
  • SGLT2 (9)
  • vascular diseases (1)
  • wave (2)
  • Sizes of these terms reflect their relevance to your search.

    Aging of the vasculature is characterized by endothelial dysfunction and arterial stiffening, two key events in the pathogenesis of cardiovascular disease (CVD). Treatment with sodium glucose transporter 2 (SGLT2) inhibitors is now known to decrease cardiovascular morbidity and mortality in type 2 diabetes. However, whether SGLT2 inhibition attenuates vascular aging is unknown. We first confirmed in a cohort of adult subjects that aging is associated with impaired endothelial function and increased arterial stiffness and that these two variables are inversely correlated. Next, we investigated whether SGLT2 inhibition with empagliflozin (Empa) ameliorates endothelial dysfunction and reduces arterial stiffness in aged mice with confirmed vascular dysfunction. Specifically, we assessed mesenteric artery endothelial function and stiffness (via flow-mediated dilation and pressure myography mechanical responses, respectively) and aortic stiffness (in vivo via pulse wave velocity and ex vivo via atomic force microscopy) in Empa-treated (14 mg/kg/day for 6 weeks) and control 80-week-old C57BL/6 J male mice. We report that Empa-treated mice exhibited improved mesenteric endothelial function compared with control, in parallel with reduced mesenteric artery and aortic stiffness. Additionally, Empa-treated mice had greater vascular endothelial nitric oxide synthase activation, lower phosphorylated cofilin, and filamentous actin content, with downregulation of pathways involved in production of reactive oxygen species. Our findings demonstrate that Empa improves endothelial function and reduces arterial stiffness in a preclinical model of aging, making SGLT2 inhibition a potential therapeutic alternative to reduce the progression of CVD in older individuals. © 2022. The Author(s).

    Citation

    Rogerio N Soares, Francisco I Ramirez-Perez, Francisco J Cabral-Amador, Mariana Morales-Quinones, Christopher A Foote, Thaysa Ghiarone, Neekun Sharma, Gavin Power, James A Smith, R Scott Rector, Luis A Martinez-Lemus, Jaume Padilla, Camila Manrique-Acevedo. SGLT2 inhibition attenuates arterial dysfunction and decreases vascular F-actin content and expression of proteins associated with oxidative stress in aged mice. GeroScience. 2022 Jun;44(3):1657-1675

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 35426600

    View Full Text